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Vaccination is the most important approach to counteract infectious diseases. Thus, the
development of new and improved vaccines for existing, emerging, and re-emerging
diseases is an area of great interest to the scientific community and general public.
Traditional approaches to subunit antigen discovery and vaccine development lack
consideration for the critical aspects of public safety and activation of relevant protective
host immunity. The availability of genomic sequences for pathogenic Brucella spp.
and their hosts have led to development of systems-wide analytical tools that have
provided a better understanding of host and pathogen physiology while also beginning
to unravel the intricacies at the host-pathogen interface. Advances in pathogen biology,
host immunology, and host-agent interactions have the potential to serve as a platform
for the design and implementation of better-targeted antigen discovery approaches. With
emphasis on Brucella spp., we probe the biological aspects of host and pathogen that
merit consideration in the targeted design of subunit antigen discovery and vaccine
development.
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INTRODUCTION
Infectious diseases account for significant human morbidity and
mortality on a worldwide basis. Among these, important subsets
of infectious diseases are those caused by intracellular bacterial
pathogens. Brucella, Ricketssia, Coxiella,Chlamydia,Burkholderia,
and Francisella are important disease causing intracellular eti-
ologic agents. These bacterial agents are included in the CDC
select agent list due to their highly infectious nature and their
potential use in acts of bioterrorism. Diseases such as salmonel-
losis, listeriosis and shigellosis are a concern as they represent
a threat to food safety. Tuberculosis is a disease caused by a
non-select intracellular pathogen but afflicts approximately one
third of the human population and accounts for 20% of all
human deaths due to infectious diseases (Martin, 2005). The
intracellular biology of these agents is the result of extensive
and complex interactions with their host that are necessary to
establish a niche permissive of pathogen survival and propaga-
tion. Despite the risk these diseases represent for public health,
there are no licensed vaccines in the United States to counter-
act many of them. This is a pressing need that is currently being
addressed by arduous efforts of the biomedical research commu-
nity. One of the main focuses of these efforts is to identify new
and more effective approaches to discover antigens for immu-
nization formulations and vaccine development. In this review,
we describe advances in the field of brucellosis and propose a
multistep, antigen discovery approach with the goal of develop-
ing vaccines protective against brucellosis and other intracellular
pathogen diseases.
Brucella spp. classification is based on host preference and vir-
ulence (Cloeckaert et al., 2002). Brucellae pathogens have been
isolated from a range of species including: Brucella melitensis
(primarily in goats and sheep), Brucella abortus (cattle), Brucella
suis (swine), Brucella ovis (sheep), Brucella canis (dogs), Brucella
ceti (dolphin, porpoise, and whale), Brucella pinnipedialis (seal),
Brucella neotomae (desert wood rat), Brucella microti (common
vole), and Brucella inopinata was recently isolated from human
patients (Scholz et al., 2010; Atluri et al., 2011). The reason for
host preference is not clear but recent reports characterizing alter-
ations in the genome attempts to explain these species-specific
observations (Wattam et al., 2009).
The incidence of human brucellosis is strongly dependent on
animal disease prevalence. Brucellosis is a disease that results in
great economic loss, particularly in the food animal production
sector. Intense regional efforts to control and eradicate animal
brucellosis have been successful in some areas but in many parts
of the world it continues to be an important disease. As a result,
brucellosis is amongst the most common zoonotic diseases with
a worldwide annual incidence of 500,000 new cases (Franco et al.,
2007). Although humans and animals are susceptible to brucel-
losis, there is variation in the clinical manifestations in different
species.
Brucellae are highly infectious to humans with an estimated
dose of only 10–100 organisms being sufficient to establish
an infection via the aerogenous route (Bossi et al., 2004). In
decreasing order of virulence, Brucella melitensis, Brucella suis,
and Brucella abortus are the agents most commonly implicated
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in human brucellosis (Bossi et al., 2004; Franco et al., 2007;
Lucero et al., 2008). Although horizontal human transmission
is possible, the most important source of human brucellosis is
respiratory or gastro-intestinal exposure to contaminated animal
tissue or unpasteurized milk and dairy food products, respec-
tively (Williams, 1970; Eckman, 1975; Taylor and Perdue, 1989;
Chomel et al., 1994; Godfroid et al., 2005; Corbel et al., 2006;
Mantur et al., 2007). After breaching mucosal barriers, Brucella
spp. infect submucosal or intraepithelial phagocytic cells and sub-
vert intracellular trafficking pathways. This allows Brucella spp.
to evade protective mechanisms of host phagocytes to establish
an intracellular niche amenable to survival and replication and
to provide a means for dissemination. Cell-mediated dissemina-
tion to distant organs, especially those of reticulendothelial and
reproductive systems, occurs via the circulatory system (Pizarro-
Cerda et al., 1998; Adams, 2002; Pappas et al., 2005; Franco et al.,
2007). The intracellular nature of Brucella spp. favors survival and
persistence by evading host immune surveillance. In up to 30%
of cases, human brucellosis develops to a chronic disease often
accompanied by a combination of undulant fever and myriad
non-specific symptoms (Atluri et al., 2011; Skendros et al., 2011).
Brucellae has been reported to successfully colonize and cause
pathological changes in a variety of organs including those of
the central nervous, hemolymphatic, digestive, respiratory, repro-
ductive, musculoskeletal, and cardiovascular systems, an aspect
that complicates diagnosis and may result in delay of treatment
(Franco et al., 2007; Mantur et al., 2007; Glynn and Lynn, 2008;
Seleem et al., 2010; Skendros et al., 2011). Even when diagnosed in
a timely manner, the recommended treatment for brucellosis con-
sists of prolonged administration of antibiotics that often fails to
completely clear the pathogen (Falagas and Bliziotis, 2006; Seleem
et al., 2010).
MOLECULAR PATHOGENESIS
In order to understand the pathomechanisms of infectious dis-
eases with clinical significance in animals and humans we must
first understand the biology of these agents, and their hosts, in
order to unravel the interactions that occur at the host-agent
interface. Furthermore, understanding of these mechanisms is
important for the development of new and effective chemothera-
peutic and prophylactic measures. Brucella spp. and other intra-
cellular pathogens have acquired mechanisms to evade host
innate protective mechanisms to readily gain access to the host
intracellular compartment. Once internalized, they evade intra-
cellular protective mechanisms and subsist and multiply free in
the cytoplasm or within vacuolar compartments. The organisms
within this intracellular niche create a focus of infectious agent
that potentially serves as a source for persistent systemic infection
and a chronic disease state.
INTERNALIZATION
Much effort has been spent elucidating the pathogenesis of
Brucella spp. Although significant and productive strides have
been made since the recognition of human brucellosis in the late
1800’s, there is much we do not yet know about the pathogen.
However, recent advances in the field have confirmed that the
pathogenesis of brucellosis is based on a dynamic and intricate
network of interactions that occur at the host-pathogen interface
during the invasion, adaptation and replication phases (Rossetti
et al., 2011). Deciphering these complex interactions will aid
us in elucidating and manipulating the molecular mechanisms
responsible for infection and development of disease (Adams,
2002).
Several bacterial and host molecular components that aid or
regulate invasion and affect downstream host-pathogen inter-
actions have been identified; however, the full extent of the
molecular components and mechanisms acting on either active
bacterial penetration or passive uptake of Brucella spp. are not
fully understood. It is well accepted that brucellae can efficiently
breach mucosal epithelial barriers and are capable of infecting
several professional phagocytic and non-phagocytic mammalian
cells (Murphy et al., 2002; Billard et al., 2005; Hernandez-Castro
et al., 2008; Watanabe et al., 2008; Garcia Samartino et al.,
2010; Velasquez et al., 2012). Furthermore, the internalization of
Brucella is a regulated process that involves interactions of sur-
face host and pathogen molecular factors. Accordingly, lipid rafts,
complement and Fc receptors are host surface entities for which
a role in Brucella spp. internalization has thus far been described
(Campbell et al., 1994; Moreno andMoriyon, 2002; Watarai et al.,
2002; Pei et al., 2008).
With respect to the pathogen, the outermost component of
brucellae is its multifunctional and heterogenous outer mem-
brane (Moriyon and Lopez-Goni, 1998; Jimenez de Bagues et al.,
2004; Bos et al., 2007; Martin-Martin et al., 2008; Pasquevich
et al., 2009). A major component of the membrane is the
LPS, an integral outer membrane molecule with three domains
(O-antigen, core oligosaccharide, and lipid A) that has a regula-
tory role in Brucella spp. internalization (Lapaque et al., 2005).
Specifically, the O-antigen not only protects the bacterium from
intracellular killing mechanisms but also controls its internal-
ization. Brucellae organisms with defects in the LPS (rough)
are internalized at a greater rate (i.e., up to 50 fold) than their
counterparts with intact LPS (smooth), but are unsuccessful in
preventing fusion of the brucellae-containing vacuole with the
lysosome (Porte et al., 2003; Jimenez de Bagues et al., 2004; Pei
et al., 2008; Haag et al., 2010). These data suggest that cell inter-
nalization of Brucella spp. is an O-antigen dependent selective
process with implications for downstream survival and repli-
cation (Figure 1). Additionally, it has been demonstrated that
O-antigen is associated with a protective effect on Brucella spp.
membranes to bactericidal polycations and is necessary for lipid-
raft dependent uptake (Moriyon and Lopez-Goni, 1998; Watarai
et al., 2002; von Bargen et al., 2012). However, recent reports
suggest that additional bacterial factors also present in rough
Brucella spp. organisms may interact with and mediate lipid
raft-dependent uptake (Martin-Martin et al., 2010). These data
suggest that while rough organisms may be internalized by lipid
raft-dependent and independent mechanisms, smooth brucel-
lae are mostly internalized via lipid raft-dependent mechanisms,
perhaps explaining the higher uptake rates observed with rough
organisms.
A role in internalization has also been described for brucellae
outer membrane proteins. A putative role for outer membrane
proteins in internalization is suggested by impaired uptake of
Frontiers in Cellular and Infection Microbiology www.frontiersin.org May 2013 | Volume 3 | Article 17 | 2
Gomez et al. Brucella subunit vaccine review
FIGURE 1 | Brucella invasion and intracellular trafficking in host
mammalian cells. Smooth Brucella is internalized in a vacuole following
interactions with host cell lipid rafts, PrPc, and SR-A. Brucella derived
β-1,2-glucans act by remodeling surface vacuolar lipid-rich domains. The
vacuole then fuses transiently with host cell lysosomes for replication-
competent bacteria. These transient interactions lead to activation of
acid-dependent genes, including type 4 secretion system. Type 4 secretion
system substrate proteins are translocated to the cytosol of the host cell
where they purportedly act to support trafficking and interactions with the
endoplasmic reticulum in order to reach the replicative vacuole. In contrast,
internalization and intracellular trafficking of rough Brucella is poorly
characterized but a role for Brucella Omp22 and Omp25 has been
demonstrated. The events that occur after internalization are not clear but
ultimately lead to lysosomal degradation.
Brucella spp. with inactivation of the two-component system
(TCS), BvrRS. The BvrRS TCS is a sensory transduction bacte-
rial system that is necessary for full expression of various outer
membrane proteins (Sola-Landa et al., 1998; Guzman-Verri et al.,
2002; Lamontagne et al., 2007; Viadas et al., 2010). Among
those, Omp22 and Omp25 are two membrane proteins for which
expression is BvrRS dependent. Targeted inactivation of genes
omp22 and omp25 impaired internalization of rough B. ovis but
not B. abortus (Manterola et al., 2007; Martin-Martin et al., 2008).
The basis for these findings is unclear, but suggested explana-
tions range from functional redundancy in the outer membrane
to a greater role for LPS in smooth agent internalization and
physical obstruction due to LPS-shielding of outer membrane
proteins.
Recent reports have identified additional proteins with a role
in Brucella spp. adhesion and internalization (Castaneda-Roldan
et al., 2006; Hernandez-Castro et al., 2008; Martin-Martin et al.,
2008; Czibener and Ugalde, 2012; Posadas et al., 2012). The
encoding genes or their protein products have homology to
adhesin or invasion factors present in other pathogens including
Bartonella bacilliformis (BMEI0216), Salmonella enterica (SP41,
BmaC), and enterohemorrhagic E. coli (Bab1_2009) (Castaneda-
Roldan et al., 2006; Hernandez-Castro et al., 2008; Czibener and
Ugalde, 2012; Posadas et al., 2012). Evidence for the involvement
of several host and pathogen components in cell internalization
of brucellae coupled with poor mechanistic understanding of
the process is a reflection of the intricacies and interdependency
acting at the host-agent interface.
INTRACELLULAR TRAFFICKING AND REPLICATION
Following internalization, intracellular bacterial pathogens are
confronted with a variety of harsh conditions within the host
cell and with which they must cope and adapt in order to
survive. Their ability to adapt by evading, resisting or sub-
verting intracellular host protective mechanisms is dictated by
structural components or elaboration of virulence factors that
promote survival, replication, persistence, and systemic dissem-
ination as necessary events to cause disease. Collectively, there
are a variety of mechanisms that intracellular pathogens have
acquired through evolutionary pressure to establish productive
intracellular infections. One of the main intracellular host pro-
tective mechanisms is degradation of pathogens within lysosomal
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compartments. Intracellular pathogens have acquired strategies
to avoid the killing mechanisms of host cells by avoiding lyso-
somal bactericidal contents through escape to the cytoplasm
prior to fusion of phagosome with the lysosome (i.e., Francisella,
Shigella, Listeria, Ricketssia), delay, or arrest of phagosome mat-
uration [i.e., Mycobacterium (early endosome), Salmonella (late
endosome)], modulation of vacuolar intracellular trafficking
pathways so as to permit interactions with host organelles crit-
ical for the establishment of a replicative niche (i.e., Legionella)
or resistance to killing by lysosomal contents, as is the case for
C. burnetii (Starr et al., 2008; Cossart and Roy, 2010; Alix et al.,
2011).
Similar to other intracellular pathogens, the complexity of
Brucella spp. pathogenesis is demonstrated by its ability to resist
intracellular killing mechanisms and reach a membrane-bound
replicative-competent niche inside host cells (Figure 1). Brucella
spp. are internalized in a lipid-raft containing vacuole that
acquires EEA-1 and Rab5 antigens following interactions with
the endocytic pathway (von Bargen et al., 2012). The surface
cholesterol-rich lipid rafts are then modified by brucellae-derived
β-1,2-glucans (Figure 1) as a necessary step for further matu-
ration of the vacuole (Briones et al., 2001; Roset et al., 2004;
von Bargen et al., 2012). As maturation continues, early mark-
ers on the Brucella-containing vacuole (BCV) are replaced with
late endocytic markers LAMP-1 and Rab7 following interactions
with late endosomal compartments. These transient interactions
between BCV and late endosomes/lysosomes are controlled to
allow vacuolar acidification and transcription of acid-dependent
bacterial factors (i.e., virB) but prevent vacuolar inclusion of
the proteolytic enzyme, cathepsin D (Boschiroli et al., 2002; von
Bargen et al., 2012). The virB operon encodes a membrane-
associated type IV secretion system (T4SS) used for the secretion
of putative bacterial factors (Figure 1) believed to act to mod-
ulate the host cell response to support maturation of the BCV
(Boschiroli et al., 2002). Although the presence of these effec-
tor proteins was only speculative for years, recent research efforts
have revealed the identity of several of these T4SS substrate pro-
teins (Figure 1) includingVceA, VceC, BPE005, BPE043, BPE123,
and BPE275 (de Jong et al., 2008; Marchesini et al., 2011).
Nonetheless, the function of these recently identified substrate
proteins remains, for the most part, undefined. Ongoing research
is focused on the identification of additional effectors and their
functions in an effort to understand the precise role that the T4SS
and its substrate molecules play in the maturation of the BCV
and establishment of the replicative niche (O’Callaghan et al.,
1999; Hong et al., 2000; Gorvel and Moreno, 2002; Celli et al.,
2003; den Hartigh et al., 2008; Nijskens et al., 2008). After BCV
acidification, the vacuole interacts with the ER via Sar1, Rab2,
and IRE-α dependent mechanisms (Celli et al., 2005; Qin et al.,
2008; Fugier et al., 2009). These interactions lead to BCV acqui-
sition of ER-specific markers that include calreticulin, calnexin,
and Sec61 (von Bargen et al., 2012). Furthermore, brucellae repli-
cation only occurs after the BCV interacts with the ER (Starr
et al., 2012; von Bargen et al., 2012). Although we have a general
understanding of the series of events leading up to Brucella spp.
intracellular replication, the post-replicative events are less clear.
Bacterial exit from infected cells is required for intercellular and
inter-host propagation (Hybiske and Stephens, 2008). A model
consisting of smooth dissociation, intracellular rough replication,
bacterial-induced cytotoxicity, and pathogen release has been sug-
gested (Turse et al., 2011). Recently, an egress model where the
replicative BCV undergoes further maturation, gains autophagic
features and exits as a membrane-bound particle, was reported;
however, re-infection of neighboring cells was only demonstrated
in human epithelial cells (HeLa) and not the macrophage, the
cell type believed to be the major site of Brucella spp. replication
(David, 2012; Starr et al., 2012).
If the host is permissible to Brucella spp. infection then
survival, replication and egress results from the ability of the
pathogen to concurrently alter the function of multiple host
systems. Indeed, active manipulation of host immune response
to promote its survival is a fundamental aspect of brucellosis.
Evasion of intracellular killing mechanisms affords brucellae the
ability to localize within a sub-cellular compartment that favors
intracellular replication. Understanding the details and applica-
ble mechanisms of pathogen biology is expected to shed light
on the identification of treatment options (Alix et al., 2011).
Alterations in intracellular trafficking resulting from host-agent
interactions at different stages of the Brucella spp. life cycle may
be expected to reveal the identity of molecular components or
pathways that play an important role in the pathogenesis of the
agent (Eriksson et al., 2003; Lucchini et al., 2005; Waddell and
Butcher, 2007; Fontan et al., 2008; Wehrly et al., 2009; Fukuto
et al., 2010; Rossetti et al., 2011; Pruneau et al., 2012). Most
importantly, it is in this intracellular voyage that brucellae actively
produce and secrete known and putative molecular effectors that
are presumed to aid in the establishment of a replicative niche
(Figure 1). Previous studies reveal that known virulence factors
such as the virB operon, vjbR, and Omp25 are upregulated in
the intracellular stage of infection (Boschiroli et al., 2002; Wang
et al., 2009). Global transcriptional analysis of the intracellular
pathogen Francisella tularensis in mouse macrophages revealed
that greater than 25% of the genes over-expressed in the intra-
cellular phase had been previously demonstrated to have a role
in replication or virulence of the pathogen (Wehrly et al., 2009).
This finding is relevant to vaccine antigen discovery and vaccine
development based on the assumption that virulence factors crit-
ical to the establishment of infection are less likely to mutate,
their expression during infection is necessary, and, hence, may
represent good vaccine candidates.
HOST PROTECTIVE IMMUNO-MECHANISMS
CELL-MEDIATED IMMUNITY
Host immunity is divided into innate and adaptive immune
responses. Due to the chronic nature of many diseases caused by
intracellular pathogens, an effective adaptive response is necessary
to control disease. Although several components of the immune
system contribute to protection against intracellular pathogens,
a cell-mediated immune response has been demonstrated to be
critical for protection against Brucella and other intracellular
pathogens such as Chlamydia, Francisella, and Mycobacterium
(Kamath et al., 2009; Shannon and Heinzen, 2009; Karunakaran
et al., 2010; Plotkin, 2010). Macrophages and T-cells play cru-
cial roles in protection. Helper T-cell mediated protection is
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primarily associated with a Th1 T-cell response and persistence
(i.e., chronic brucellosis) with a Th2 response (Golding et al.,
2001; Giambartolomei et al., 2002; Yingst and Hoover, 2003;
Rafiei et al., 2006; Skendros et al., 2007, 2011; Titball, 2008;
Perkins et al., 2010). More specifically, studies have demonstrated
protective contributions for IFN-γ, IL-12, and TNF-α against
brucellosis (Zhan and Cheers, 1995; Zhan et al., 1996; Murphy
et al., 2001; Baldwin and Parent, 2002; Brandao et al., 2012). In
addition to the Th1 response, CD8+ T cells also contribute to
protection as mice deficient in MHCI presentation fail to control
Brucella spp. infection (Oliveira and Splitter, 1995). Protection
elicited by passive transfer of CD4+ and CD8+ T cell subsets cor-
roborate these findings and highlight the importance of T cell
cytotoxicity and T-cell driven cytokine-mediated orchestration
of the immune response in protection against brucellosis (Araya
et al., 1989). The function of dendritic cells in innate and adap-
tive immunity and their presence at mucosal surfaces makes their
study in brucellosis important (Iwasaki, 2007). Dendritic cells
have been demonstrated to be permissive of brucellae infection
and replication (Billard et al., 2005; Bosio and Dow, 2005). The
role of dendritic cells in protection against brucellosis is not com-
pletely understood; however, brucellae have been demonstrated to
regulate the response of dendritic cells as detailed below (Billard
et al., 2005; Iwasaki, 2007). The γδ T-cells may also have a role in
the control of brucellosis; however, the precise mechanism for this
protection is undefined (Bessoles et al., 2011; Skyberg et al., 2011).
Lastly, natural killer cells have cell cytotoxic capabilities and are
able to secrete IFN-γ, but a direct role for this cell type in the con-
trol of acute brucellosis is not clear (Fernandes et al., 1995; Gao
et al., 2011; Vivier et al., 2011). Collectively, these data support a
pivotal role for T cell-mediated immunity in protection against
brucellosis. Also, these findings support the assumption that T-
cell immunity is the single most important response mediating
protection from brucellosis (Araya et al., 1989; Elzer et al., 1994;
Hoffmann and Houle, 1995; Ko and Splitter, 2003).
HUMORAL IMMUNITY
The contributory role of antibody to protection against brucellae
is less defined than the role of T-cell immunity; however, precise
protective mechanisms of humoral immunity against intracellu-
lar pathogens may rely on a focused combination of factors that
include antibody isotype and function. Protection studies with
animal models deficient in B-cell function indicate that this cell
type is not necessary for protection against primary infection,
yet passive transfer of antibodies from immunized or exposed
animals confer protection on naïve animals against brucellosis
(Araya et al., 1989; Casadevall and Pirofski, 2006; Goenka et al.,
2011). The results suggest that while antibodies have a protective
role against re-infection with Brucella spp., similar to Francisella
spp. and Listeria spp., their role in protection against primary
infection is less explicit (Casadevall and Pirofski, 2006). These
data further imply that innate or alternate immuno-protective
mechanisms that precede development of humoral immunity
are sufficient to control primary infection and the synergistic
and/or inhibitory contributions of specific antibodies need to
be further explored (Araya et al., 1989; Casadevall and Pirofski,
2006; Titball, 2008; Shannon and Heinzen, 2009; Goenka et al.,
2011). While antibodies may be protective against secondary
exposure, this protective effect is not always apparent in passive
immunity transfer studies suggesting a synergistic, rather than
an absolute, protective role for humoral immunity. The basis
of these findings may aid in understanding antibody immuno-
protective mechanisms. This knowledge will aid in understanding
the specific mechanisms that are relevant to protection against
Brucella spp. and shed light onto the pathogen-specific design and
development of therapeutic and prophylactic measures.
IMMUNOPATHOLOGY
Intracellular pathogens have strategies or contain structural com-
ponents to evade and remain undetected by the host immune sys-
tem. Under evolutionary pressure, Brucella spp. have developed
elaborate and sophisticated survival-promoting mechanisms en
route to its establishment as an important pathogen of mam-
mals. These mechanisms endow brucellae with the ability to
complete its life cycle in a protected, intracellular, vacuolar com-
partment. This is evidenced by its capability to manipulate and
evade innate and adaptive immunity and other host protective
mechanisms through structural component and secreted soluble
factor functionality (Barquero-Calvo et al., 2009). Among these,
the TcpB molecule is a multifunctional soluble Brucella-derived
factor that alters cytoskeleton function, inhibits dendritic cell
maturation and disrupts the MyD88 signaling pathway (Salcedo
et al., 2008; Radhakrishnan et al., 2009, 2011; Sengupta et al.,
2010; Chaudhary et al., 2012). A recent report also attributes
TcpB an inhibitory function on cytotoxic T-cells during chronic
brucellosis (Durward et al., 2012). Another important molecule
which effects the immune system is PrpA. PrpA is a Brucella-
derived B-cell mitogen that supports B cell secretion of the
immuno-suppressive cytokine, IL-10 (Spera et al., 2006). This
study is in line with the recent finding that B-cells promote bru-
cellae colonization in the mouse (Goenka et al., 2011). The LPS
is also a multifunctional, Brucella-derived factor with immuno-
regulatory capabilities. Specifically, Brucella spp. LPS has weak
endotoxin (immunostimulatory) properties, protects from com-
plement, and controls antigen presentation through formation
of persistent LPS-MHC II complexes (Lapaque et al., 2006;
Barrionuevo et al., 2008). Several outer membrane proteins have
also been demonstrated to support Brucella spp. infection and
survival. Brucellae Omp25 regulates TNF-α secretion and pre-
vents apoptosis of macrophages (Gross et al., 2000; Jubier-Maurin
et al., 2001; Billard et al., 2007). Anti-apoptotic properties have
been demonstrated for the Omp2b porin in macrophages and
yeast (He et al., 2006; Laloux et al., 2010). Interestingly, recent
reports describe apoptosis of B. abortus infected T-lymphocytes
and astrocytes (Garcia Samartino et al., 2010; Velasquez et al.,
2012). The basis for this selectivity is not clear but the inherent
cellular role in promoting brucellosis may be important.
IMMUNIZATION APPROACHES
Vaccination is themost efficient and inexpensive method to coun-
teract infectious diseases (Oyewumi et al., 2010). Historically,
vaccinology has relied on immunization with live-attenuated
organisms or subunit antigens as two of the main approaches to
elicit host immunoprotection against infectious agents. However,
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the success of the immunization approach used against any given
pathogen is influenced by multiple factors including pathogen
biology, safety, and acceptable levels of protection.
LIVE ATTENUATEDVACCINATION
Although not always the best option from a biosafety standpoint,
live-attenuated vaccination to combat disease caused by intracel-
lular infectious agents is the approach that, in most cases, confers
the highest degree and longest duration of protection (de Veer
and Meeusen, 2011; Levitz and Golenbock, 2012). The superior
protective efficacy of live attenuated vaccines against intracellular
pathogens relies in part on their ability to elicit robust cell-
mediated immune responses (Seder andHill, 2000; Titball, 2008).
Accordingly, protective vaccines exist for Brucella spp. and other
intracellular pathogens but aspects such as residual virulence,
hypersensitivity, and lack of protective efficacy across age groups
makes them unfit for immunization of humans and, therefore,
many have failed to meet approval standards for human use in
the United States (Blasco and Diaz, 1993; Schurig et al., 2002;
Waag et al., 2002; Ashford et al., 2004; Martin, 2005; Wallach
et al., 2008; Rockx-Brouwer et al., 2012). Accordingly, intense
research efforts have been placed on identifying live-attenuated
vaccines directed at brucellae with an acceptable combination
of safety and protective properties (Titball, 2008; Ficht et al.,
2009). For instance, identification of virulence-related Brucella
spp. genes identified via high-throughput mutagenesis studies
has resulted in several promising vaccine candidates that are cur-
rently in various stages of development (Wu et al., 2006; Ficht
et al., 2009; Perkins et al., 2010). Even though live-attenuated
organisms provide adequate levels and long-lasting protection,
there are concerns associated with the production, stability, and
administration of such vaccines (Levitz and Golenbock, 2012).
Manipulation and production of live attenuated vaccine strains
often necessitate stringent bio-containment. Additionally, risk for
reversion to virulence exists and differentiation between exposed
and immunized subjects can be challenging and complicate
immuno-surveillance efforts. Lastly, there is an ever-present risk
of disease in both healthy and the ever-growing population of
immune-compromised subjects (Frey, 2007; Chen et al., 2010;
Oyewumi et al., 2010).
SUBUNIT VACCINATION
In efforts to address concerns associated with live-attenuated
vaccination, subunit vaccinology is increasingly gaining support
as an alternative approach. However, there are many challenges
associated with the development of a protective subunit vaccine
against Brucella spp. One of the major impediments to progress in
this field can be attributed to the difficulty involved in the identi-
fication of protective antigens. Second, delivery of soluble subunit
antigen primarily targets a humoral immune response as opposed
to the crucial cell-mediated immunity needed to protect against
Brucella spp.; however, recent developments in delivery of antigen
are designed to address these concerns. Lastly, it is unlikely that
protection resulting from subunit vaccination against Brucella
spp. will depend on a single antigen. An approach to identify anti-
gens that act synergistically to elicit protective immunity must be
considered (Titball, 2008; Plotkin, 2010).
Traditional approaches to subunit vaccine development, such
as those based on protective efficacy of bacterial fractions with
subsequent identification of specific protective antigens, and
the use of serology to identify immuno-dominant antigens, has
been a common practice (Rappuoli, 2000; Chen et al., 2011).
These methods can be tedious and expensive and often give
an unsatisfactory outcome. As a result, these approaches have
led to the identification of several subunit antigens that elicit
marginal or variable levels of protection against brucellosis and
which seldom approach the levels of protection elicited by live-
attenuated vaccination (Corbel, 1976; Tabatabai and Pugh, 1994;
Oliveira and Splitter, 1996; Al-Mariri et al., 2001; Velikovsky
et al., 2003; Ashford et al., 2004; Cassataro et al., 2005, 2007;
Martin, 2005; Pakzad et al., 2009; Pasquevich et al., 2009). The
limited success of this approach and advances in the understand-
ing of host-Brucella spp. interactions has triggered the search
for more efficient approaches to antigen discovery and vaccine
development.
In the development of subunit vaccines, antigen selection and
delivery platform are two key components that merit careful con-
sideration (de Veer and Meeusen, 2011; Levitz and Golenbock,
2012). Significant advances in the fields of immunology, host-
agent interactions, microbiology, and bioinformatics have pro-
vided insight for the strategic design of targeted tools with
protective antigen identification capabilities
ANTIGEN SELECTION
In the wake of emerging and re-emerging infectious diseases and
bioterrorist threats, the need for protective vaccines approved for
human use is a priority of research on agents such as Brucella
spp. in the United States. To this end, a clear understanding of the
molecular interactions between Brucella spp. and the host and the
identification of antigenic determinants that stimulate protective
host immune responses are fundamental and vital pieces of infor-
mation that need to be considered. However, the development
of a vaccine is further complicated by the peculiarity of Brucella
spp. in that it lacks many of the classical virulence factors and has
specific mechanisms to counteract host protective mechanisms in
order to promote its persistence (Atluri et al., 2011).
One important deterrent to the advancement of subunit vac-
cine development is the historically ineffective manner of antigen
discovery. The identification of immunogenic proteins based
solely on humoral immunity is a method that is often suggested or
experimentally explored, but this approach undermines or does
not always correlate with immune responses determined to have
clear relevance to protection against Brucella spp. and other intra-
cellular pathogens, i.e., T cell immunity (Rappuoli, 2000; Liang
et al., 2010; Chen et al., 2011; Zhao et al., 2011). The availabil-
ity of complete genomic sequences for many brucellae and their
hosts has made the study of functional genomics, proteomics,
and immunomics in the context of host-brucellae interactions
possible.
The results obtained from these comprehensive experiments
have started to yield data that will increase the understand-
ing of not only the pathogenesis of disease but will also aid
in characterizing molecule-specific immunogenicity. Notably, the
availability of genomic sequences has led to the development
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of algorithms for the in silico prediction of proteins with desir-
able structural, (i.e., outer membrane proteins), functional (i.e.,
adhesin), and antigenic (B cell and T cell epitopes) determinants
(Figure 2). Following from these predictions, each protein can
be expressed and tested for immunogenic and protective poten-
tial, in an approach known as reverse vaccinology (Rappuoli,
2000; Sette and Rappuoli, 2010). Taking into consideration host
protective mechanisms, antigen selection via the reverse vaccinol-
ogy approach can be tailored to identify antigens that contain
a combination of antigenic determinants and functional, con-
served, and structural properties (He et al., 2010). In its nascent
stage, the use of reverse vaccinology has yielded promising results
and progress is being made toward the development of vaccines
against several pathogens (Sette and Rappuoli, 2010; Bagnoli
et al., 2011). Additionally, this approach is often used in an effort
to narrow the number of candidate antigens to a working pool
for validation and evaluation. Specifically, reverse vaccinology
has aided in the identification of antigens that have protective
antigenic determinants from various intracellular pathogens
including Chlamydia, Ehrlichia, Francisella, Mycobacterium, and
may represent a viable approach to the identification of anti-
gens for immunization against brucellosis (McMurry et al., 2007;
Finco et al., 2011; Zvi et al., 2011; Liebenberg et al., 2012;
Sundaramurthi et al., 2012).
In addition, availability of genomic sequences has led to the
development of whole proteome assays that have been used to
determine antigen-specific antibody responses against Brucella
spp. (Liang et al., 2010). A clear advantage of these assays is
that they will aid in overcoming some limitations of traditional
assays such as 2D gels, which are based on total bacterial lysates
and its signal is dependent on the quantity of antigen in the
preparation. While this approach will aid in screening immuno-
dominant antigens that have potential vaccinogen value, this
approach must be used as an ancillary rather than the sole cri-
terion for antigen selection as humoral immunity does not always
correlate with the more protective responses as described above.
FIGURE 2 | Vaccine candidate selection approach. An important aspect of
a vaccine candidate is antigenicity. In silico analysis of available genomic
sequences can aid in the selection of open reading frames that code for
desired properties such as T and B cell epitopes, subcellular localization (i.e.,
outer membrane proteins), and a lack of homology to host proteins.
Secondly, antigens with evidence for a role in pathogenesis are often
targeted in the identification of vaccine candidates. Identification of factors
important for invasion, survival, and replication can be performed via
mutagenesis studies in the mouse or cell culture systems. Additionally,
comparative transcriptomic and proteomic studies of wild type and mutant
pathogen strains can be carried out to identify potential virulence factors.
Lastly, the priming of an immune response to a specific antigen relies on its
availability. In order to identify antigenic targets present during infection,
infection-dependent gene expression studies may reveal suitable targets.
Frontiers in Cellular and Infection Microbiology www.frontiersin.org May 2013 | Volume 3 | Article 17 | 7
Gomez et al. Brucella subunit vaccine review
In addition, knowledge of the precise brucellae-specific protective
mechanisms of humoral immunity (i.e., antibody isotype) may
aid in further focusing selection on the most relevant targets.
One other important aspect of infectious diseases that is rel-
evant to vaccination is host-pathogen interactions as these may
reveal the dynamics of bacterial antigen quantity and shed light
into their putative role in infection (Figure 2). The availability
of genomic sequences has led to development of assays, notably
microarrays, targeted at the study of host-agent interactions at
the gene and protein levels. First of all, suitable pathogen antigen
targets must be present in sufficient quantities during infection
in order to be recognized by the immune system. As described
above, brucellae secrete factors in order to evade intracellular
protective mechanisms and establish a niche in which they can
replicate. Putatively, these antigens are secreted into the cytoplasm
to alter normal function of host cells and manipulate intracellu-
lar trafficking (Figures 2, 3). As a result, these factors or those
associated with them (i.e., secretion system) can potentially be
processed and presented in MHC I molecules via the endogenous
pathway (Figure 3), in alternate presentation pathways to CD8+
T cells, a T cell subset important for protection against brucel-
losis (Oliveira and Splitter, 1995; Blanchard and Shastri, 2010;
Grillo et al., 2012). Similar toMycobacterium and Salmonella, pro-
tection studies in Brucella have demonstrated that immunization
FIGURE 3 | Model for antigen presentation during Brucella infection.
Upon internalization of Brucella, the conditions in the vacuole trigger changes
in the gene expression profiles. Interactions or fusion with the lysosomes
result in changes that support intracellular replication or lead to Brucella
degradation, respectively. Peptides that result from degradation are
presented via MHCII to helper T cells or, presumptively, to cytotoxic T cells
via the vacuolar pathway of cross-presentation. Intracellular Brucella proteins
are processed for presentation via MHCI molecules. Proteins are processed
into peptides by host proteosomes in the cytosol. Peptides are loaded into
MHCI molecules in the endoplasmic reticulum and packaged in the golgi
apparatus for transportation to the surface of the host cell for presentation
and activation of T cells.
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with bacterial factors that are up-regulated during infection are of
value in eliciting protective immunity (Rollenhagen et al., 2004;
Lowry et al., 2011; Kao et al., 2012). Although work with Brucella
spp. is limited, evidence for early success merits further investi-
gation. Additionally, these antigens could potentially be virulence
factors and serve as better antigens in a vaccine formulation based
on the presumption that they are conserved andmay be less prone
to mutation due to their role in pathogenesis. For instance, LPS
and the T4SS are important virulence factors with vital roles in
intracellular survival that are present in the pathogenic strains
B. melitensis, B. abortus, and B. suis (Carle et al., 2006; Wattam
et al., 2009).
Overall, we propose that antigen selection for the development
of subunit immunization regimen for Brucella spp. must include
antigens that: (1) Contain antigenic determinants with protec-
tive relevance, a process that may be aided by in silico analysis
of genomic sequences; (2) Are present at adequate levels during
infection in an effort to provide a target for recognition and elim-
ination of infected host cells by the primed immune system; and
(3) Have a link to the pathogenesis of the agent with the intent
to minimize the risk of mutation and resistance. We propose that
consideration of host protective mechanisms and antigenic deter-
minants, in vivo expression of pathogen molecular factors, and
brucellae virulence-related factors in an antigen selection scheme
will lead to the identification of immuno-protective Brucella spp.
antigens (Figure 2).
ENHANCING PROTECTIVE IMMUNE RESPONSES OF
SUBUNIT VACCINES
Two important considerations in subunit vaccination are adju-
vant or delivery vehicle and route of immunization. Adjuvants
are compounds co-administered with antigen that have the abil-
ity to affect the potency and quality of antigen-specific immune
responses. In part due to their ability to stimulate innate immu-
nity, adjuvants influence the ensuing adaptive immune response
directed at the antigen (Coffman et al., 2010). Research efforts
aimed at deciphering the stimulatory effects of adjuvants have
aided in their rational selection for inclusion in subunit vaccine
formulations when the general protective immuno-mechanisms
against the pathogen of interest are known. Adjuvants almost
invariably stimulate humoral immunity but can be selected based
on their ability to stimulate a combination of Th1, Th2, Th17,
and CD8+ T-cell responses (Coffman et al., 2010). From these,
targeting activation and proliferation of CD8+ T cells and stimu-
lation of a Th1 response are important when considering vaccine
development for brucellae. While Poly-IC, imiquimods, CpG,
ISCOMS (immuno-stimulatory complexes) have been demon-
strated to result in Th1 and CD8+ T cells, CAF10 and MPL
stimulate Th1 skewed responses (Coffman et al., 2010; Duewell
et al., 2011). Despite the role that Th1 and CD8+ T cell responses
play in protection against brucellosis, the majority of Brucella spp.
subunit immunization studies have and continue to primarily use
Alum (aluminum salts) or Freund’s adjuvant (FA) in immuniza-
tion formulations (Pasquevich et al., 2009, 2011; Lowry et al.,
2011; Yang et al., 2011a,b; Fu et al., 2012; Goel and Bhatnagar,
2012; Jain et al., 2012; Li et al., 2012). This practice is inconsistent
with the protective mechanisms against brucellosis since Alum
is primarily associated with a Th2 response, FA elicits a mixed
Th1/Th2 response and both have no demonstrated ability to stim-
ulate of CD8+ T cell responses (Coffman et al., 2010); however,
the use of Alum may be associated with its acceptance for use in
human subjects.
The field of adjuvant/antigen subunit vaccine formulation is
an area that merits further exploration in the context of Brucella
spp. vaccinology. An immunization study revealed that protection
against virulent brucellae challenge was dependent on adjuvant
where co-administration with CpG ODN, a TLR agonist, but
not non-CpG ODN or protein (P39) alone resulted in protec-
tion against challenge (Al-Mariri et al., 2001). Another study
demonstrated that mice inoculated with L7/L12 in liposomes had
a greater ability to clear Brucella spp. than mice immunized with
antigen and FA (Mallick et al., 2007). Nonetheless, another study
reported no difference in protection regardless of whether MPL,
FA, or Alum was used (Velikovsky et al., 2003).
The use of recombinant vectors is another viable option for
delivering subunit antigens. Viral and bacterial vectors that are
safe for use in vaccine formulations have been developed and are
currently used for immunization with subunit antigens. One of
the appealing characteristics of this type of vaccination platform
is their ability to induce cell-mediated immunity, particularly
cytotoxic T lymphocytes (Harms et al., 2009; Rollier et al., 2011).
Given the role of these cells in protection against intracellular
pathogens, this is an appealing approach in brucellosis subunit
vaccinology. The use of E. coli as the delivery vehicle for recom-
binant Brucella spp. antigens (i.e., P39) demonstrated that this
platform induced only marginal levels of protection (Al-Mariri,
2010; Al-Mariri et al., 2012). However, the combination of the
recombinant bacterial vector with a TLR agonist enhanced the
protective effect of the formulation to a level that approached
that elicited by a live-attenuated vaccine strain (Al-Mariri et al.,
2012). A point of consideration is that these studies used the
non-invasive E. coli strain BL-21, which perhaps affected down-
stream antigen processing as a result of the mode of antigen
uptake (i.e., active vs. passive) by antigen presenting cells. The
elaboration and use of a recombinant invasive E. coli strain
to deliver antigens revealed promising results in mouse stud-
ies (Harms et al., 2009; Gupta et al., 2012). Lastly, the use
of Lactococcus and Ochrobactrum over-expressing Brucella spp.
antigens has also been evaluated and shown to confer partial pro-
tection against challenge (Saez et al., 2012). However, the fact
that these two bacterial strains are avirulent may again have an
effect on antigen presentation as they may be highly attenuated
intracellularly and potentially result in limited antigen produc-
tion or be internalized by APCs through routes that do not fully
stimulate desired immunity. Other promising bacterial vectors
such as Salmonella, an intracellular pathogen, are also available
but have not been evaluated in the context of brucellosis (Galen
et al., 2009). The advantages of using the Salmonella live vaccine
are that this bacterium is a potent stimulator of innate immu-
nity, targets internalization by antigen presenting cells and has
an intracellular lifestyle with a well-defined capacity for protein
production and secretion in the intracellular compartment. The
use of recombinant viral vectors is another area that may prove
useful in delivery of subunit antigens. Despite its widespread use
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in the literature, its use in brucellosis is limited (Perkins et al.,
2010).
Another area that merits consideration in Brucella subunit
vaccinology is the route of immunization. Immunization with
Brucella LPS complexed with Neisseria OMP resulted in better
protection to intranasal challenge following parenteral compared
to intranasal immunization (Bhattacharjee et al., 2006). However,
potential antigen degradation via the mucosal route was not
accounted for in this study. Similarly, lipoproteins co-delivered
with cholera toxin conferred protection against Brucella challenge
in animals immunized via the mucosal route but the degree of
protection was not as high as that obtained in mice immunized
via the parenteral route (Pasquevich et al., 2011). The identifica-
tion of measures to enhance mucosal protective immunity is an
area of interest in brucellosis vaccinology as the main route of
brucellae infection is through mucosal surfaces.
Entrapment of antigen in particles for delivery is yet another
option for subunit immunization. In the context of Brucella sub-
unit vaccinology little is known about particulate antigen delivery.
Several physical aspects of particles have been linked to their effect
on the immune system and include particle size, chemical compo-
sition, erosion rate, surface chemistry, and immunization route as
thoroughly reviewed elsewhere (Oyewumi et al., 2010; Rice-Ficht
et al., 2010). Other than affecting size-dependent penetration of
anatomical barriers, there is evidence that supports particle size
playing a role on the quality of the ensuing immunity relative
to humoral and/or cell-mediated responses following immuniza-
tion (Oyewumi et al., 2010). Additionally, the use of particles
may aid in preventing antigen degradation when mucosa is the
intended route of immunization, enhance uptake by dendritic
cells, and macrophages, and act as a focus for prolonged anti-
gen release acting as a self-boosting mechanism (Oyewumi et al.,
2010). In brucellosis research, delivery of antigen in the form of
outer membrane vesicles, in liposomes, or in polymeric parti-
cles has been explored to a limited extent (Estevan et al., 2006;
Munoz et al., 2006; Mallick et al., 2007; Jain-Gupta et al., 2012).
Therefore, antigen delivery in polymeric particles is an area with
encouraging potential in subunit antigen immunization against
brucellosis. Given that the physical properties of particles can
have an effect on the resulting immune response, these can poten-
tially be designed to deliver antigen and stimulate antigen-specific
protective immunity against brucellosis.
CONCLUSIONS
The antigen, delivery vehicle or adjuvant, and delivery route are
key components that merit careful consideration in the devel-
opment of a subunit vaccine against brucellosis (de Veer and
Meeusen, 2011; Levitz and Golenbock, 2012). However, the iden-
tification of suitable antigens may represent the most challenging
aspect. Significant advances in the fields of immunology, micro-
biology, and bioinformatics and their application to the under-
standing of host-agent interactions have provided insight for
the strategic design of better-targeted tools that aim to identify
protective antigens.
There are important criteria that must be met in an effort
to maximize the probability of arriving at the identification of
a suitable antigen. First, the candidate immunogen must have
antigenic determinants. As discussed above, a T-cell mediated
response is generally critical for protection against brucellosis.
Therefore, the inclusion of antigens with MHC I and MHC II
epitopes for the priming of CD8+ and CD4+ T cells, respec-
tively, should be included in the screening of candidate antigens.
Accordingly, an antigen delivery vehicle that targets both the
endogenous and exogenous antigen presentation pathways needs
to be considered. In order to target protective humoral immu-
nity, a deeper understanding of the precise mechanisms and
associated antibody isotypes, quantities and temporal dynam-
ics involved in the protection against Brucella spp. is needed.
Secondly, the level of antigen present during infection must be
considered for two main reasons. One, high antigen levels dur-
ing infection may indicate that those antigens are necessary for
adaptation or replication of the pathogen. Two, availability of
suitable quantities of antigen to serve as a source for antigen
processing and presentation may enhance elimination of infected
cells as a result of recognition by the immune system. Thirdly,
the adjuvant or delivery platform selection is a critical compo-
nent of vaccine formulation. The delivery system must support
the development of a Th1 and CD8+ T cell immune responses,
consistent with the immuno-mechanisms that confer host pro-
tection against brucellae. Finally, appropriate combination of
adjuvants and/or delivery systems may be required to potenti-
ate desired immune responses that aid in enhancing protective
efficacy. We propose that all these parameters merit considera-
tion in the discovery of Brucella spp. subunit antigens and vaccine
development.
REFERENCES
Adams, L. G. (2002). The pathology
of brucellosis reflects the out-
come of the battle between the
host genome and the Brucella
genome. Vet. Microbiol. 90,
553–561.
Alix, E., Mukherjee, S., and Roy, C.
R. (2011). Subversion of mem-
brane transport pathways by vac-
uolar pathogens. J. Cell Biol. 195,
943–952.
Al-Mariri, A. (2010). Protection of
BALB/c mice against Brucella
melitensis 16 M infection induced
by vaccination with live Escherchia
coli expression Brucella P39 protein.
Vaccine 28, 1766–1770.
Al-Mariri, A., Mahmoud, N. H., and
Hammoud, R. (2012). Efficacy
evaluation of live Escherichia coli
expression Brucella P39 protein
combined with CpG oligodeoxynu-
cleotides vaccine against Brucella
melitensis 16M, in BALB/c mice.
Biologicals 40, 140–145.
Al-Mariri, A., Tibor, A., Mertens, P., De
Bolle, X., Michel, P., Godefroid, J.,
et al. (2001). Protection of BALB/c
mice against Brucella abortus 544
challenge by vaccination with bac-
terioferritin or P39 recombinant
proteins with CpG oligodeoxynu-
cleotides as adjuvant. Infect. Immun.
69, 4816–4822.
Araya, L. N., Elzer, P. H., Rowe,
G. E., Enright, F. M., and
Winter, A. J. (1989). Temporal
development of protective cell-
mediated and humoral immunity
in BALB/c mice infected with
Brucella abortus. J. Immunol. 143,
3330–3337.
Ashford, D. A., di Pietra, J., Lingappa,
J., Woods, C., Noll, H., Neville,
B., et al. (2004). Adverse events
in humans associated with acci-
dental exposure to the livestock
brucellosis vaccine RB51. Vaccine
22, 3435–3439.
Atluri, V. L., Xavier, M. N., de Jong,
M. F., den Hartigh, A. B., and
Tsolis, R. E. (2011). Interactions
of the human pathogenic Brucella
species with their hosts. Annu. Rev.
Microbiol. 65, 523–541.
Bagnoli, F., Baudner, B., Mishra, R. P.,
Bartolini, E., Fiaschi, L., Mariotti,
P., et al. (2011). Designing the next
generation of vaccines for global
public health. OMICS 15, 545–566.
Baldwin, C. L., and Parent, M. (2002).
Fundamentals of host immune
response against Brucella abortus:
Frontiers in Cellular and Infection Microbiology www.frontiersin.org May 2013 | Volume 3 | Article 17 | 10
Gomez et al. Brucella subunit vaccine review
what the mouse model has revealed
about control of infection. Vet.
Microbiol. 90, 367–382.
Barquero-Calvo, E., Conde-Alvarez, R.,
Chacon-Diaz, C., Quesada-Lobo,
L., Martirosyan, A., Guzman-Verri,
C., et al. (2009). The differen-
tial interaction of Brucella and
Ochrobactrum with innate immu-
nity reveals traits related to the evo-
lution of stealthy pathogens. PLoS
ONE 4:e5893. doi: 10.1371/journal.
pone.0005893
Barrionuevo, P., Cassataro, J., Delpino,
M. V., Zwerdling, A., Pasquevich,
K. A., Garcia Samartino, C., et al.
(2008). Brucella abortus inhibits
major histocompatibility complex
class II expression and antigen pro-
cessing through interleukin-6 secre-
tion via Toll-like receptor 2. Infect.
Immun. 76, 250–262.
Bessoles, S., Ni, M., Garcia-Jimenez,
S., Sanchez, F., and Lafont, V.
(2011). Role of NKG2D and its lig-
ands in the anti-infectious activ-
ity of Vgamma9Vdelta2 T cells
against intracellular bacteria. Eur. J.
Immunol. 41, 1619–1628.
Bhattacharjee, A. K., Izadjoo, M. J.,
Zollinger, W. D., Nikolich, M.
P., and Hoover, D. L. (2006).
Comparison of protective efficacy
of subcutaneous versus intranasal
immunization of mice with a
Brucella melitensis lipopolysaccha-
ride subunit vaccine. Infect. Immun.
74, 5820–5825.
Billard, E., Cazevieille, C., Dornand,
J., and Gross, A. (2005). High
susceptibility of human dendritic
cells to invasion by the intracellular
pathogens Brucella suis, B. abortus,
and B. melitensis. Infect. Immun. 73,
8418–8424.
Billard, E., Dornand, J., and Gross,
A. (2007). Brucella suis prevents
human dendritic cell maturation
and antigen presentation through
regulation of tumor necrosis factor
alpha secretion. Infect. Immun. 75,
4980–4989.
Blanchard, N., and Shastri, N. (2010).
Cross-presentation of peptides from
intracellular pathogens by MHC
class I molecules. Ann. N.Y. Acad.
Sci. 1183, 237–250.
Blasco, J. M., and Diaz, R. (1993).
Brucella melitensis Rev-1 vaccine as
a cause of human brucellosis. Lancet
342, 805.
Bos, M. P., Robert, V., and Tommassen,
J. (2007). Biogenesis of the gram-
negative bacterial outer membrane.
Annu. Rev. Microbiol. 61, 191–214.
Boschiroli, M. L., Ouahrani-Bettache,
S., Foulongne, V., Michaux-
Charachon, S., Bourg, G.,
Allardet-Servent, A., et al. (2002).
The Brucella suis virB operon
is induced intracellularly in
macrophages. Proc. Natl. Acad.
Sci. U.S.A. 99, 1544–1549.
Bosio, C. M., and Dow, S. W. (2005).
Francisella tularensis induces aber-
rant activation of pulmonary
dendritic cells. J. Immunol. 175,
6792–6801.
Bossi, P., Tegnell, A., Baka, A., Van
Loock, F., Hendriks, J., Werner, A.,
et al. (2004). Bichat guidelines for
the clinical management of brucel-
losis and bioterrorism-related bru-
cellosis. Euro Surveill. 9, E15–E16.
Brandao, A. P., Oliveira, F. S., Carvalho,
N. B., Vieira, L. Q., Azevedo, V.,
Macedo, G. C., et al. (2012). Host
susceptibility to Brucella abortus
infection is more pronounced
in IFN-gamma knockout than
IL-12/beta2-microglobulin double-
deficient mice. Clin. Dev. Immunol.
2012:589494. doi: 10.1155/2012/
589494
Briones, G., Inon de Iannino, N., Roset,
M., Vigliocco, A., Paulo, P. S., and
Ugalde, R. A. (2001). Brucella abor-
tus cyclic beta-1, 2-glucan mutants
have reduced virulence in mice and
are defective in intracellular replica-
tion inHeLa cells. Infect. Immun. 69,
4528–4535.
Campbell, G. A., Adams, L. G., and
Sowa, B. A. (1994). Mechanisms
of binding of Brucella abortus to
mononuclear phagocytes from
cows naturally resistant or suscep-
tible to brucellosis. Vet. Immunol.
Immunopathol. 41, 295–306.
Carle, A., Hoppner, C., Ahmed Aly,
K., Yuan, Q., den Dulk-Ras, A.,
Vergunst, A., et al. (2006). The
Brucella suis type IV secretion
system assembles in the cell enve-
lope of the heterologous host
Agrobacterium tumefaciens and
increases IncQ plasmid pLS1 recipi-
ent competence. Infect. Immun. 74,
108–117.
Casadevall, A., and Pirofski, L. A.
(2006). A reappraisal of humoral
immunity based on mechanisms
of antibody-mediated protection
against intracellular pathogens. Adv.
Immunol. 91, 1–44.
Cassataro, J., Estein, S. M., Pasquevich,
K. A., Velikovsky, C. A., de la
Barrera, S., Bowden, R., et al.
(2005). Vaccination with the recom-
binant Brucella outer membrane
protein 31 or a derived 27-amino-
acid synthetic peptide elicits a CD4+
T helper 1 response that protects
against Brucella melitensis infection.
Infect. Immun. 73, 8079–8088.
Cassataro, J., Velikovsky, C. A., Bruno,
L., Estein, S. M., de la Barrera, S.,
Bowden, R., et al. (2007). Improved
immunogenicity of a vaccination
regimen combining a DNA vaccine
encoding Brucella melitensis outer
membrane protein 31 (Omp31)
and recombinant Omp31 boost-
ing. Clin. Vaccine Immunol. 14,
869–874.
Castaneda-Roldan, E. I., Ouahrani-
Bettache, S., Saldana, Z., Avelino, F.,
Rendon, M. A., Dornand, J., et al.
(2006). Characterization of SP41, a
surface protein of Brucella associ-
ated with adherence and invasion of
host epithelial cells. Cell Microbiol.
8, 1877–1887.
Celli, J., de Chastellier, C., Franchini,
D. M., Pizarro-Cerda, J., Moreno,
E., and Gorvel, J. P. (2003). Brucella
evades macrophage killing via VirB-
dependent sustained interactions
with the endoplasmic reticulum.
J. Exp. Med. 198, 545–556.
Celli, J., Salcedo, S. P., and Gorvel, J.
P. (2005). Brucella coopts the small
GTPase Sar1 for intracellular repli-
cation. Proc. Natl. Acad. Sci. U.S.A.
102, 1673–1678.
Chaudhary, A., Ganguly, K.,
Cabantous, S., Waldo, G. S.,
Micheva-Viteva, S. N., Nag, K.,
et al. (2012). The Brucella TIR-
like protein TcpB interacts with
the death domain of MyD88.
Biochem. Biophys. Res. Commun.
417, 299–304.
Chen, C., Dow, C., Wang, P., Sidney,
J., Read, A., Harmsen, A., et al.
(2011). Identification of CD4+ T
cell epitopes in C. burnetii anti-
gens targeted by antibody responses.
PLoS ONE 6:e17712. doi: 10.1371/
journal.pone.0017712
Chen, D. J., Osterrieder, N., Metzger,
S. M., Buckles, E., Doody, A. M.,
DeLisa, M. P., et al. (2010). Delivery
of foreign antigens by engineered
outer membrane vesicle vaccines.
Proc. Natl. Acad. Sci. U.S.A. 107,
3099–3104.
Chomel, B. B., DeBess, E. E.,
Mangiamele, D. M., Reilly, K.
F., Farver, T. B., Sun, R. K., et al.
(1994). Changing trends in the epi-
demiology of human brucellosis in
California from 1973 to 1992: a shift
toward foodborne transmission.
J. Infect. Dis. 170, 1216–1223.
Cloeckaert, A., Vizcaino, N., Paquet,
J. Y., Bowden, R. A., and Elzer,
P. H. (2002). Major outer mem-
brane proteins of Brucella spp.: past,
present and future. Vet. Microbiol.
90, 229–247.
Coffman, R. L., Sher, A., and Seder,
R. A. (2010). Vaccine adjuvants:
putting innate immunity to work.
Immunity 33, 492–503.
Corbel, M. J. (1976). The immuno-
genic activity of ribosomal fractions
derived from Brucella abortus.
J. Hyg. (Lond.) 76, 65–74.
Corbel, M. J., World Health
Organization, Food and Agriculture
Organization of the United Nations,
International Office of Epizootics,
and ebrary Inc. (2006). Brucellosis
in Humans and Animals. Geneva:
World Health Organization.
Cossart, P., and Roy, C. R. (2010).
Manipulation of host membrane
machinery by bacterial pathogens.
Curr. Opin. Cell Biol. 22, 547–554.
Czibener, C., and Ugalde, J. E. (2012).
Identification of a unique gene clus-
ter of Brucella spp. that mediates
adhesion to host cells. Microbes
Infect. 14, 79–85.
David, R. (2012). Cellular microbi-
ology: an unconventional exit for
Brucella. Nat. Rev. Microbiol. 10,
160.
de Jong, M. F., Sun, Y. H., den Hartigh,
A. B., van Dijl, J. M., and Tsolis,
R. M. (2008). Identification of VceA
and VceC, twomembers of the VjbR
regulon that are translocated into
macrophages by the Brucella type IV
secretion system.Mol. Microbiol. 70,
1378–1396.
den Hartigh, A. B., Rolan, H. G., de
Jong, M. F., and Tsolis, R. M. V.
(2008). VirB3 to VirB6 and VirB8
to VirB11, but not VirB7, are essen-
tial for mediating persistence of
Brucella in the reticuloendothelial
system. J. Bacteriol. 190, 4427–4436.
de Veer, M., and Meeusen, E. (2011).
New developments in vaccine
research–unveiling the secret of
vaccine adjuvants. Discov. Med. 12,
195–204.
Duewell, P., Kisser, U., Heckelsmiller,
K., Hoves, S., Stoitzner, P., Koernig,
S., et al. (2011). ISCOMATRIX
adjuvant combines immune activa-
tion with antigen delivery to den-
dritic cells in vivo leading to effec-
tive cross-priming of CD8+ T cells.
J. Immunol. 187, 55–63.
Durward, M., Radhakrishnan, G.,
Harms, J., Bareiss, C., Magnani, D.,
and Splitter, G. A. (2012). Active
evasion of CTL mediated killing
and low quality responding CD8+
T cells contribute to persistence of
Brucellosis. PLoS ONE 7:e34925.
doi: 10.1371/journal.pone.0034925
Eckman, M. R. (1975). Brucellosis
linked to Mexican cheese. JAMA
232, 636–637.
Elzer, P. H., Jacobson, R. H., Jones,
S. M., Nielsen, K. H., Douglas,
J. T., and Winter, A. J. (1994).
Antibody-mediated protection
against Brucella abortus in BALB/c
mice at successive periods after
infection: variation between vir-
ulent strain 2308 and attenuated
Frontiers in Cellular and Infection Microbiology www.frontiersin.org May 2013 | Volume 3 | Article 17 | 11
Gomez et al. Brucella subunit vaccine review
vaccine strain 19. Immunology 82,
651–658.
Eriksson, S., Lucchini, S., Thompson,
A., Rhen, M., and Hinton, J. C.
(2003). Unravelling the biology
of macrophage infection by gene
expression profiling of intracellular
Salmonella enterica. Mol. Microbiol.
47, 103–118.
Estevan, M., Gamazo, C., Grillo, M. J.,
Del Barrio, G. G., Blasco, J. M., and
Irache, J. M. (2006). Experiments
on a sub-unit vaccine encapsulated
in microparticles and its efficacy
against Brucella melitensis in mice.
Vaccine 24, 4179–4187.
Falagas, M. E., and Bliziotis, I. A.
(2006). Quinolones for treatment
of human brucellosis: critical
review of the evidence from micro-
biological and clinical studies.
Antimicrob. Agents Chemother. 50,
22–33.
Fernandes, D. M., Benson, R., and
Baldwin, C. L. (1995). Lack of a role
for natural killer cells in early con-
trol of Brucella abortus 2308 infec-
tions in mice. Infect. Immun. 63,
4029–4033.
Ficht, T. A., Kahl-McDonagh, M. M.,
Arenas-Gamboa, A. M., and Rice-
Ficht, A. C. (2009). Brucellosis: the
case for live, attenuated vaccines.
Vaccine 27(Suppl. 4), D40–D43.
Finco, O., Frigimelica, E., Buricchi, F.,
Petracca, R., Galli, G., Faenzi, E.,
et al. (2011). Approach to discover
T- and B-cell antigens of intracellu-
lar pathogens applied to the design
of Chlamydia trachomatis vaccines.
Proc. Natl. Acad. Sci. U.S.A. 108,
9969–9974.
Fontan, P., Aris, V., Ghanny, S.,
Soteropoulos, P., and Smith, I.
(2008). Global transcriptional pro-
file of Mycobacterium tuberculosis
during THP-1 human macrophage
infection. Infect. Immun. 76,
717–725.
Franco, M. P., Mulder, M., Gilman, R.
H., and Smits, H. L. (2007). Human
brucellosis. Lancet Infect. Dis. 7,
775–786.
Frey, J. (2007). Biological safety con-
cepts of genetically modified live
bacterial vaccines. Vaccine 25,
5598–5605.
Fu, S., Xu, J., Li, X., Xie, Y., Qiu, Y.,
Du, X., et al. (2012). Immunization
of mice with recombinant protein
CobB or AsnC confers protection
against Brucella abortus infection.
PLoS ONE 7:e29552. doi: 10.1371/
journal.pone.0029552
Fugier, E., Salcedo, S. P., de Chastellier,
C., Pophillat, M., Muller, A.,
Arce-Gorvel, V., et al. (2009). The
glyceraldehyde-3-phosphate dehy-
drogenase and the small GTPase
Rab 2 are crucial for Brucella repli-
cation. PLoS Pathog. 5:e1000487.
doi: 10.1371/journal.ppat.1000487
Fukuto, H. S., Svetlanov, A., Palmer,
L. E., Karzai, A. W., and Bliska,
J. B. (2010). Global gene expres-
sion profiling of Yersinia pestis
replicating inside macrophages
reveals the roles of a putative
stress-induced operon in regulating
type III secretion and intracellular
cell division. Infect. Immun. 78,
3700–3715.
Galen, J. E., Pasetti, M. F., Tennant, S.,
Ruiz-Olvera, P., Sztein, M. B., and
Levine, M. M. (2009). Salmonella
enterica serovar Typhi live vec-
tor vaccines finally come of age.
Immunol. Cell. Biol. 87, 400–412.
Gao, N., Jennings, P., Guo, Y., and Yuan,
D. (2011). Regulatory role of nat-
ural killer (NK) cells on antibody
responses to Brucella abortus. Innate
Immun. 17, 152–163.
Garcia Samartino, C., Delpino, M. V.,
Pott Godoy, C., Di Genaro, M.
S., Pasquevich, K. A., Zwerdling,
A., et al. (2010). Brucella abortus
induces the secretion of proinflam-
matory mediators from glial cells
leading to astrocyte apoptosis. Am.
J. Pathol. 176, 1323–1338.
Giambartolomei, G. H., Delpino, M.
V., Cahanovich, M. E., Wallach, J.
C., Baldi, P. C., Velikovsky, C. A.,
et al. (2002). Diminished produc-
tion of T helper 1 cytokines corre-
lates with T cell unresponsiveness
to Brucella cytoplasmic proteins in
chronic human brucellosis. J. Infect.
Dis. 186, 252–259.
Glynn, M. K., and Lynn, T. V. (2008).
Brucellosis. J. Am. Vet. Med. Assoc.
233, 900–908.
Godfroid, J., Cloeckaert, A., Liautard, J.
P., Kohler, S., Fretin, D., Walravens,
K., et al. (2005). From the discov-
ery of the Malta fever’s agent to
the discovery of a marine mammal
reservoir, brucellosis has continu-
ously been a re-emerging zoonosis.
Vet. Res. 36, 313–326.
Goel, D., and Bhatnagar, R. (2012).
Intradermal immunization with
outer membrane protein 25 pro-
tects Balb/c mice from virulent B.
abortus 544. Mol. Immunol. 51,
159–168.
Goenka, R., Parent, M. A., Elzer, P.
H., and Baldwin, C. L. (2011). B
cell-deficient mice display markedly
enhanced resistance to the intra-
cellular bacterium Brucella abortus.
J. Infect. Dis. 203, 1136–1146.
Golding, B., Scott, D. E., Scharf, O.,
Huang, L. Y., Zaitseva, M., Lapham,
C., et al. (2001). Immunity and
protection against Brucella abortus.
Microbes Infect. 3, 43–48.
Gorvel, J. P., and Moreno, E. (2002).
Brucella intracellular life: from inva-
sion to intracellular replication. Vet.
Microbiol. 90, 281–297.
Grillo, M. J., Blasco, J. M., Gorvel, J. P.,
Moriyon, I., and Moreno, E. (2012).
What have we learned from brucel-
losis in the mouse model? Vet. Res.
43, 29.
Gross, A., Terraza, A., Ouahrani-
Bettache, S., Liautard, J. P., and
Dornand, J. (2000). In vitro Brucella
suis infection prevents the pro-
grammed cell death of human
monocytic cells. Infect. Immun. 68,
342–351.
Gupta, V. K., Radhakrishnan, G.,
Harms, J., and Splitter, G. (2012).
Invasive Escherichia coli vaccines
expressing Brucella melitensis outer
membrane proteins 31 or 16 or
periplasmic protein BP26 confer
protection in mice challenged with
B.melitensis. Vaccine 30, 4017–4022.
Guzman-Verri, C., Manterola, L., Sola-
Landa, A., Parra, A., Cloeckaert,
A., Garin, J., et al. (2002). The
two-component system BvrR/BvrS
essential for Brucella abortus vir-
ulence regulates the expression
of outer membrane proteins with
counterparts in members of the
Rhizobiaceae. Proc. Natl. Acad. Sci.
U.S.A. 99, 12375–12380.
Haag, A. F., Myka, K. K., Arnold,
M. F., Caro-Hernandez, P., and
Ferguson, G. P. (2010). Importance
of Lipopolysaccharide and Cyclic
beta-1, 2-Glucans in Brucella-
Mammalian Infections. Int. J.
Microbiol. 2010:124509. doi:
10.1155/2010/124509
Harms, J. S., Durward, M. A., Magnani,
D. M., and Splitter, G. A. (2009).
Evaluation of recombinant invasive,
non-pathogenic Eschericia coli
as a vaccine vector against the
intracellular pathogen, Brucella.
J. Immune Based Ther. Vaccines. 7:1.
doi: 10.1186/1476-8518-7-1
He, Y., Reichow, S., Ramamoorthy, S.,
Ding, X., Lathigra, R., Craig, J. C.,
et al. (2006). Brucella melitensis trig-
gers time-dependent modulation
of apoptosis and down-regulation
of mitochondrion-associated gene
expression in mouse macrophages.
Infect. Immun. 74, 5035–5046.
He, Y., Xiang, Z., and Mobley, H. L.
(2010). Vaxign: the first web-based
vaccine design program for reverse
vaccinology and applications for




Rodriguez, A., Puente, J. L.,
and Suarez-Guemes, F. (2008).
The BMEI0216 gene of Brucella
melitensis is required for inter-
nalization in HeLa cells. Microb.
Pathog. 44, 28–33.
Hoffmann, E. M., and Houle, J. J.
(1995). Contradictory roles for anti-
body and complement in the inter-
action of Brucella abortus with
its host. Crit. Rev. Microbiol. 21,
153–163.
Hong, P. C., Tsolis, R. M., and Ficht,
T. A. (2000). Identification of genes
required for chronic persistence of
Brucella abortus in mice. Infect.
Immun. 68, 4102–4107.
Hybiske, K., and Stephens, R. S. (2008).
Exit strategies of intracellular
pathogens. Nat. Rev. Microbiol. 6,
99–110.
Iwasaki, A. (2007). Mucosal dendritic
cells. Annu. Rev. Immunol. 25,
381–418.
Jain, S., Afley, P., and Kumar, S.
(2012). Immunological responses to
recombinant cysteine synthase A of
Brucella abortus in BALB/c mice.
World J. Microbiol. Biotechnol. 29,
907–913.
Jain-Gupta, N., Contreras-Rodriguez,
A., Vemulapalli, R., Witonsky, S. G.,
Boyle, S.M., and Sriranganathan, N.
(2012). Pluronic P85 enhances the
efficacy of outer membrane vesicles
as a subunit vaccine against Brucella
melitensis challenge in mice. FEMS
Immunol. Med. Microbiol. 66,
436–444.
Jimenez de Bagues, M. P., Terraza,
A., Gross, A., and Dornand, J.
(2004). Different responses of
macrophages to smooth and
rough Brucella spp.: relationship
to virulence. Infect. Immun. 72,
2429–2433.
Jubier-Maurin, V., Boigegrain, R. A.,
Cloeckaert, A., Gross, A., Alvarez-
Martinez, M. T., Terraza, A., et al.
(2001). Major outer membrane
protein Omp25 of Brucella suis is
involved in inhibition of tumor
necrosis factor alpha produc-
tion during infection of human
macrophages. Infect. Immun. 69,
4823–4830.
Kamath, A. T., Rochat, A. F.,
Christensen, D., Agger, E. M.,
Andersen, P., Lambert, P. H., et al.
(2009). A liposome-based mycobac-
terial vaccine induces potent adult
and neonatal multifunctional T cells
through the exquisite targeting of
dendritic cells. PLoS ONE 4:e5771.
doi: 10.1371/journal.pone.0005771
Kao, F. F., Mahmuda, S., Pinto,
R., Triccas, J. A., West, N. P.,
and Britton, W. J. (2012). The
secreted lipoprotein, MPT83, of
Mycobacterium tuberculosis is rec-
ognized during human tuberculosis
and stimulates protective immunity
Frontiers in Cellular and Infection Microbiology www.frontiersin.org May 2013 | Volume 3 | Article 17 | 12
Gomez et al. Brucella subunit vaccine review
in mice. PLoS ONE 7:e34991. doi:
10.1371/journal.pone.0034991
Karunakaran, K. P., Yu, H., Foster,
L. J., and Brunham, R. C. (2010).
Development of a Chlamydia
trachomatis T cell Vaccine. Hum.
Vaccin. 6, 676–680.
Ko, J., and Splitter, G. A. (2003).
Molecular host-pathogen interac-
tion in brucellosis: current under-
standing and future approaches to
vaccine development for mice and
humans. Clin. Microbiol. Rev. 16,
65–78.
Laloux, G., Deghelt, M., de Barsy, M.,
Letesson, J. J., and De Bolle, X.
(2010). Identification of the essen-
tial Brucella melitensis porin Omp2b
as a suppressor of Bax-induced cell
death in yeast in a genome-wide
screening. PLoS ONE 5:e13274. doi:
10.1371/journal.pone.0013274
Lamontagne, J., Butler, H., Chaves-
Olarte, E., Hunter, J., Schirm,
M., Paquet, C., et al. (2007).
Extensive cell envelope modulation
is associated with virulence in
Brucella abortus. J. Proteome Res. 6,
1519–1529.
Lapaque, N., Forquet, F., de Chastellier,
C., Mishal, Z., Jolly, G., Moreno,
E., et al. (2006). Characterization of
Brucella abortus lipopolysaccharide
macrodomains as mega rafts. Cell.
Microbiol. 8, 197–206.
Lapaque, N., Moriyon, I., Moreno, E.,
and Gorvel, J. P. (2005). Brucella
lipopolysaccharide acts as a viru-
lence factor. Curr. Opin. Microbiol.
8, 60–66.
Levitz, S. M., and Golenbock, D.
T. (2012). Beyond empiricism:
informing vaccine development
through innate immunity research.
Cell 148, 1284–1292.
Li, X., Xu, J., Xie, Y., Qiu, Y., Fu, S.,
Yuan, X., et al. (2012). Vaccination
with recombinant flagellar proteins
FlgJ and FliN induce protection
against Brucella abortus 544 infec-
tion in BALB/c mice. Vet. Microbiol.
161, 137–144.
Liang, L., Leng, D., Burk, C., Nakajima-
Sasaki, R., Kayala, M. A., and
Atluri, V. L., et al. (2010). Large
scale immune profiling of infected
humans and goats reveals differen-
tial recognition of Brucella meliten-
sis antigens. PLoS Negl. Trop. Dis.
4:e673. doi: 10.1371/journal.pntd.
0000673
Liebenberg, J., Pretorius, A., Faber,
F. E., Collins, N. E., Allsopp, B.
A., and van Kleef, M. (2012).
Identification of Ehrlichia ruminan-
tium proteins that activate cellular
immune responses using a reverse
vaccinology strategy. Vet. Immunol.
Immunopathol. 145, 340–349.
Lowry, J. E., Isaak, D. D., Leonhardt,
J. A., Vernati, G., Pate, J. C., and
Andrews, G. P. (2011). Vaccination
with Brucella abortus recombinant
in vivo-induced antigens reduces
bacterial load and promotes clear-
ance in amouse model for infection.
PLoS ONE 6:e17425. doi: 10.1371/
journal.pone.0017425
Lucchini, S., Liu, H., Jin, Q.,
Hinton, J. C., and Yu, J. (2005).
Transcriptional adaptation of
Shigella flexneri during infection of
macrophages and epithelial cells:
insights into the strategies of a
cytosolic bacterial pathogen. Infect.
Immun. 73, 88–102.
Lucero, N. E., Ayala, S. M., Escobar, G.
I., and Jacob, N. R. (2008). Brucella
isolated in humans and animals in
Latin America from 1968 to 2006.
Epidemiol. Infect. 136, 496–503.
Mallick, A. I., Singha, H., Chaudhuri,
P., Nadeem, A., Khan, S. A., Dar,
K. A., et al. (2007). Liposomised
recombinant ribosomal L7/L12 pro-
tein protects BALB/c mice against
Brucella abortus 544 infection.
Vaccine 25, 3692–3704.
Manterola, L., Guzman-Verri, C.,
Chaves-Olarte, E., Barquero-Calvo,
E., de Miguel, M. J., Moriyon, I.,
et al. (2007). BvrR/BvrS-controlled
outer membrane proteins Omp3a
and Omp3b are not essential for
Brucella abortus virulence. Infect.
Immun. 75, 4867–4874.
Mantur, B. G., Amarnath, S. K., and
Shinde, R. S. (2007). Review of
clinical and laboratory features of
human brucellosis. Indian J. Med.
Microbiol. 25, 188–202.
Marchesini, M. I., Herrmann, C. K.,
Salcedo, S. P., Gorvel, J. P., and
Comerci, D. J. (2011). In search of
Brucella abortus type IV secretion
substrates: screening and identifica-
tion of four proteins translocated
into host cells through VirB system.
Cell Microbiol. 13, 1261–1274.
Martin, C. (2005). The dream of a vac-
cine against tuberculosis; new vac-
cines improving or replacing BCG?
Eur. Respir. J. 26, 162–167.
Martin-Martin, A. I., Caro-Hernandez,
P., Orduna, A., Vizcaino, N.,
and Fernandez-Lago, L. (2008).
Importance of the Omp25/Omp31
family in the internalization and
intracellular replication of virulent
B. ovis in murine macrophages
and HeLa cells. Microbes Infect. 10,
706–710.
Martin-Martin, A. I., Vizcaino, N.,
and Fernandez-Lago, L. (2010).
Cholesterol, ganglioside GM1 and
class A scavenger receptor con-
tribute to infection by Brucella
ovis and Brucella canis in murine
macrophages. Microbes Infect. 12,
246–251.
McMurry, J. A., Kimball, S., Lee, J.
H., Rivera, D., Martin, W., Weiner,
D. B., et al. (2007). Epitope-
driven TB vaccine development:
a streamlined approach using
immuno-informatics, ELISpot
assays, and HLA transgenic mice.
Curr. Mol. Med. 7, 351–368.
Moreno, E., and Moriyon, I. (2002).
Brucella melitensis: a nasty bug with
hidden credentials for virulence.
Proc. Natl. Acad. Sci. U.S.A. 99, 1–3.
Moriyon, I., and Lopez-Goni, I. (1998).
Structure and properties of the
outer membranes of Brucella abor-
tus and Brucella melitensis. Int.
Microbiol. 1, 19–26.
Munoz, P. M., Estevan, M., Marin,
C. M., Jesus De Miguel, M., Jesus
Grillo, M., Barberan, M., et al.
(2006). Brucella outer membrane
complex-loaded microparticles as
a vaccine against Brucella ovis in
rams. Vaccine 24, 1897–1905.
Murphy, E., Robertson, G. T., Parent,
M., Hagius, S. D., Roop, R. M.
2nd., Elzer, P. H., et al. (2002).
Major histocompatibility com-
plex class I and II expression on
macrophages containing a vir-
ulent strain of Brucella abortus
measured using green fluorescent
protein-expressing brucellae and
flow cytometry. FEMS Immunol.
Med. Microbiol. 33, 191–200.
Murphy, E. A., Sathiyaseelan, J., Parent,
M. A., Zou, B., and Baldwin,
C. L. (2001). Interferon-gamma is
crucial for surviving a Brucella
abortus infection in both resistant
C57BL/6 and susceptible BALB/c
mice. Immunology 103, 511–518.
Nijskens, C., Copin, R., De Bolle,
X., and Letesson, J. J. (2008).
Intracellular rescuing of a B.
melitensis 16M virB mutant by
co-infection with a wild type strain.
Microb. Pathog. 45, 134–141.
O’Callaghan, D., Cazevieille, C.,
Allardet-Servent, A., Boschiroli,
M. L., Bourg, G., Foulongne, V.,
et al. (1999). A homologue of the
Agrobacterium tumefaciens VirB
and Bordetella pertussis Ptl type IV
secretion systems is essential for
intracellular survival of Brucella
suis.Mol. Microbiol. 33, 1210–1220.
Oliveira, S. C., and Splitter, G. A.
(1995). CD8+ type 1 CD44hi CD45
RBlo T lymphocytes control intra-
cellular Brucella abortus infection as
demonstrated in major histocom-
patibility complex class I- and class
II-deficient mice. Eur. J. Immunol.
25, 2551–2557.
Oliveira, S. C., and Splitter, G. A.
(1996). Immunization of mice with
recombinant L7/L12 ribosomal
protein confers protection against
Brucella abortus infection. Vaccine
14, 959–962.
Oyewumi, M. O., Kumar, A., and Cui,
Z. (2010). Nano-microparticles as
immune adjuvants: correlating par-
ticle sizes and the resultant immune
responses. Expert Rev. Vaccines 9,
1095–1107.
Pakzad, I., Rezaee, A., Rasaee, M. J.,
Tabbaraee, B., and Delpisheh, A.
(2009). Immunogencity of HSA-
L7/L12 (Brucella abortus ribosomal
protein) in an animal model. Iran J.
Immunol. 6, 12–21.
Pappas, G., Akritidis, N., Bosilkovski,
M., and Tsianos, E. (2005).
Brucellosis. N. Engl. J. Med.
352, 2325–2336.
Pasquevich, K. A., Estein, S. M., Garcia
Samartino, C., Zwerdling, A., Coria,
L. M., Barrionuevo, P., et al. (2009).
Immunization with recombinant
Brucella species outer membrane
protein Omp16 or Omp19 in adju-
vant induces specific CD4+ and
CD8+ T cells as well as systemic
and oral protection against Brucella
abortus infection. Infect. Immun. 77,
436–445.
Pasquevich, K. A., Ibanez, A. E.,
Coria, L. M., Garcia Samartino,
C., Estein, S. M., Zwerdling, A.,
et al. (2011). An oral vaccine
based on U-Omp19 induces pro-
tection against B. abortus mucosal
challenge by inducing an adaptive
IL-17 immune response in mice.
PLoS ONE 6:e16203. doi: 10.1371/
journal.pone.0016203
Pei, J., Turse, J. E., and Ficht, T. A.
(2008). Evidence of Brucella abortus
OPS dictating uptake and restrict-
ing NF-kappaB activation inmurine
macrophages. Microbes Infect. 10,
582–590.
Perkins, S. D., Smither, S. J., and Atkins,
H. S. (2010). Towards a Brucella vac-
cine for humans. FEMS Microbiol.
Rev. 34, 379–394.
Pizarro-Cerda, J., Moreno, E.,
Sanguedolce, V., Mege, J. L.,
and Gorvel, J. P. (1998). Virulent
Brucella abortus prevents lyso-
some fusion and is distributed
within autophagosome-like com-
partments. Infect. Immun. 66,
2387–2392.
Plotkin, S. A. (2010). Correlates of
protection induced by vaccina-
tion. Clin. Vaccine Immunol. 17,
1055–1065.
Porte, F., Naroeni, A., Ouahrani-
Bettache, S., and Liautard, J. P.
(2003). Role of the Brucella suis
lipopolysaccharide O antigen in
phagosomal genesis and in inhibi-
tion of phagosome-lysosome fusion
Frontiers in Cellular and Infection Microbiology www.frontiersin.org May 2013 | Volume 3 | Article 17 | 13
Gomez et al. Brucella subunit vaccine review
in murine macrophages. Infect.
Immun. 71, 1481–1490.
Posadas, D. M., Ruiz-Ranwez, V.,
Bonomi, H. R., Martin, F. A., and
Zorreguieta, A. (2012). BmaC, a
novel autotransporter of Brucella
suis, is involved in bacterial adhe-
sion to host cells. Cell Microbiol. 14,
965–982.
Pruneau, L., Emboule, L., Gely, P.,
Marcelino, I., Mari, B., Pinarello, V.,
et al. (2012). Global gene expression
profiling of Ehrlichia ruminantium
at different stages of development.
FEMS Immunol. Med. Microbiol. 64,
66–73.
Qin, Q. M., Pei, J., Ancona, V., Shaw, B.
D., Ficht, T. A., and de Figueiredo, P.
(2008). RNAi screen of endoplasmic
reticulum-associated host factors
reveals a role for IRE1alpha in
supporting Brucella replication.
PLoS Pathog. 4:e1000110. doi:
10.1371/journal.ppat.1000110
Radhakrishnan, G. K., Harms, J.
S., and Splitter, G. A. (2011).
Modulation of microtubule dynam-
ics by a TIR domain protein
from the intracellular pathogen
Brucella melitensis. Biochem. J. 439,
79–83.
Radhakrishnan, G. K., Yu, Q., Harms,
J. S., and Splitter, G. A. (2009).
Brucella TIR Domain-containing
Protein Mimics Properties of
the Toll-like Receptor Adaptor
Protein TIRAP. J. Biol. Chem. 284,
9892–9898.
Rafiei, A., Ardestani, S. K., Kariminia,
A., Keyhani, A., Mohraz, M., and
Amirkhani, A. (2006). Dominant
Th1 cytokine production in early
onset of human brucellosis followed
by switching towards Th2 along
prolongation of disease. J. Infect. 53,
315–324.
Rappuoli, R. (2000). Reverse vacci-
nology. Curr. Opin. Microbiol. 3,
445–450.
Rice-Ficht, A. C., Arenas-Gamboa, A.
M., Kahl-McDonagh, M. M., and
Ficht, T. A. (2010). Polymeric parti-
cles in vaccine delivery. Curr. Opin.
Microbiol. 13, 106–112.
Rockx-Brouwer, D., Chong, A., Wehrly,
T. D., Child, R., Crane, D. D., Celli,
J., et al. (2012). Low dose vacci-
nation with attenuated Francisella
tularensis strain SchuS4 mutants
protects against tularemia indepen-
dent of the route of vaccination.
PLoS ONE 7:e37752. doi: 10.1371/
journal.pone.0037752
Rollenhagen, C., Sorensen, M., Rizos,
K., Hurvitz, R., and Bumann, D.
(2004). Antigen selection based on
expression levels during infection
facilitates vaccine development
for an intracellular pathogen.
Proc. Natl. Acad. Sci. U.S.A. 101,
8739–8744.
Rollier, C. S., Reyes-Sandoval, A.,
Cottingham, M. G., Ewer, K., and
Hill, A. V. (2011). Viral vectors
as vaccine platforms: deployment
in sight. Curr. Opin. Immunol.
23, 377–382.
Roset, M. S., Ciocchini, A. E., Ugalde, R.
A., and Inon de Iannino, N. (2004).
Molecular cloning and characteri-
zation of cgt, the Brucella abortus
cyclic beta-1, 2-glucan transporter
gene, and its role in virulence. Infect.
Immun. 72, 2263–2271.
Rossetti, C. A., Galindo, C. L., Garner,
H. R., and Adams, L. G. (2011).
Transcriptional profile of the
intracellular pathogen Brucella
melitensis following HeLa cells
infection. Microb. Pathog. 51,
338–344.
Saez, D., Fernandez, P., Rivera, A.,
Andrews, E., and Onate, A. (2012).
Oral immunization of mice with
recombinant Lactococcus lactis
expressing Cu, Zn superoxide dis-
mutase of Brucella abortus triggers
protective immunity. Vaccine 30,
1283–1290.
Salcedo, S. P., Marchesini, M. I.,
Lelouard, H., Fugier, E., Jolly, G.,
Balor, S., et al. (2008). Brucella
control of dendritic cell maturation
is dependent on the TIR-containing
protein Btp1. PLoS Pathog. 4:e21.
doi: 10.1371/journal.ppat.0040021
Scholz, H. C., Nockler, K., Gollner, C.,
Bahn, P., Vergnaud, G., Tomaso, H.,
et al. (2010). Brucella inopinata sp.
nov., isolated from a breast implant
infection. Int. J. Syst. Evol. Microbiol.
60, 801–808.
Schurig, G. G., Sriranganathan, N., and
Corbel, M. J. (2002). Brucellosis
vaccines: past, present and future.
Vet. Microbiol. 90, 479–496.
Seder, R. A., and Hill, A. V. (2000).
Vaccines against intracellular infec-
tions requiring cellular immunity.
Nature 406, 793–798.
Seleem, M. N., Boyle, S. M.,
and Sriranganathan, N. (2010).
Brucellosis: a re-emerging zoonosis.
Vet. Microbiol. 140, 392–398.
Sengupta, D., Koblansky, A., Gaines, J.,
Brown, T., West, A. P., Zhang, D.,
et al. (2010). Subversion of innate
immune responses by Brucella
through the targeted degradation
of the TLR signaling adapter, MAL.
J. Immunol. 184, 956–964.
Sette, A., and Rappuoli, R. (2010).
Reverse vaccinology: developing
vaccines in the era of genomics.
Immunity 33, 530–541.
Shannon, J. G., and Heinzen, R. A.
(2009). Adaptive immunity to the
obligate intracellular pathogen
Coxiella burnetii. Immunol. Res. 43,
138–148.
Skendros, P., Boura, P., Chrisagis,
D., and Raptopoulou-Gigi, M.
(2007). Diminished percentage of
CD4+ T-lymphocytes expressing
interleukine-2 receptor alpha in
chronic brucellosis. J. Infect. 54,
192–197.
Skendros, P., Pappas, G., and Boura, P.
(2011). Cell-mediated immunity in
human brucellosis. Microbes Infect.
13, 134–142.
Skyberg, J. A., Thornburg, T., Rollins,
M., Huarte, E., Jutila, M. A., and
Pascual, D. W. (2011). Murine and
bovine gammadelta T cells enhance
innate immunity against Brucella
abortus infections. PLoS ONE
6:e21978. doi: 10.1371/journal.
pone.0021978
Sola-Landa, A., Pizarro-Cerda, J.,
Grillo, M. J., Moreno, E., Moriyon,
I., Blasco, J. M., et al. (1998). A
two-component regulatory system
playing a critical role in plant
pathogens and endosymbionts is
present in Brucella abortus and
controls cell invasion and virulence.
Mol. Microbiol. 29, 125–138.
Spera, J. M., Ugalde, J. E., Mucci, J.,
Comerci, D. J., and Ugalde, R. A.
(2006). A B lymphocyte mitogen
is a Brucella abortus virulence fac-
tor required for persistent infection.
Proc. Natl. Acad. Sci. U.S.A. 103,
16514–16519.
Starr, T., Child, R., Wehrly, T. D.,
Hansen, B., Hwang, S., Lopez-Otin,
C., et al. (2012). Selective subversion
of autophagy complexes facilitates
completion of the Brucella intracel-
lular cycle. Cell Host Microbe 11,
33–45.
Starr, T., Ng, T. W., Wehrly, T. D.,
Knodler, L. A., and Celli, J. (2008).
Brucella intracellular replica-
tion requires trafficking through
the late endosomal/lysosomal
compartment. Traffic 9, 678–694.
Sundaramurthi, J. C., Brindha,
S., Shobitha, S. R., Swathi, A.,
Ramanandan, P., and Hanna, L.
E. (2012). In silico identification
of potential antigenic proteins
and promiscuous CTL epitopes in
Mycobacterium tuberculosis. Infect.
Genet. Evol. 12, 1312–1318.
Tabatabai, L. B., and Pugh, G. W.
Jr. (1994). Modulation of immune
responses in Balb/c mice vaccinated
with Brucella abortus Cu-Zn super-
oxide dismutase synthetic peptide
vaccine. Vaccine 12, 919–924.
Taylor, J. P., and Perdue, J. N. (1989).
The changing epidemiology of
human brucellosis in Texas,
1977–1986. Am. J. Epidemiol. 130,
160–165.
Titball, R. W. (2008). Vaccines against
intracellular bacterial pathogens.
Drug Discov. Today 13, 596–600.
Turse, J. E., Pei, J., and Ficht, T.
A. (2011). Lipopolysaccharide-
deficient Brucella variants arise
spontaneously during infection.
Front. Microbiol. 2:54. doi: 10.3389/
fmicb.2011.00054
Velasquez, L. N., Delpino, M. V.,
Ibanez, A. E., Coria, L. M., Miraglia,
M. C., Scian, R., et al. (2012).
Brucella abortus induces apoptosis
of human T lymphocytes. Microbes
Infect. 14, 639–650.
Velikovsky, C. A., Goldbaum, F. A.,
Cassataro, J., Estein, S., Bowden,
R. A., Bruno, L., et al. (2003).
Brucella lumazine synthase elicits a
mixed Th1-Th2 immune response
and reduces infection in mice chal-
lenged with Brucella abortus 544
independently of the adjuvant for-
mulation used. Infect. Immun. 71,
5750–5755.
Viadas, C., Rodriguez, M. C., Sangari,
F. J., Gorvel, J. P., Garcia-Lobo,
J. M., and Lopez-Goni, I. (2010).
Transcriptome analysis of the
Brucella abortus BvrR/BvrS two-
component regulatory system.
PLoS ONE 5:e10216. doi: 10.1371/
journal.pone.0010216
Vivier, E., Raulet, D. H., Moretta, A.,
Caligiuri, M. A., Zitvogel, L., Lanier,
L. L., et al. (2011). Innate or adap-
tive immunity? The example of nat-
ural killer cells. Science 331, 44–49.
von Bargen, K., Gorvel, J. P., and
Salcedo, S. P. (2012). Internal affairs:
investigating the Brucella intracel-
lular lifestyle. FEMS Microbiol. Rev.
36, 533–562.
Waag, D. M., England, M. J.,
Tammariello, R. F., Byrne, W.
R., Gibbs, P., Banfield, C. M., et al.
(2002). Comparative efficacy and
immunogenicity of Q fever chloro-
form:methanol residue (CMR) and
phase I cellular (Q-Vax) vaccines in
cynomolgus monkeys challenged by
aerosol. Vaccine 20, 2623–2634.
Waddell, S. J., and Butcher, P. D.
(2007). Microarray analysis of
whole genome expression of intra-
cellular Mycobacterium tuberculosis.
Curr. Mol. Med. 7, 287–296.
Wallach, J. C., Ferrero, M. C., Victoria
Delpino, M., Fossati, C. A., and
Baldi, P. C. (2008). Occupational
infection due to Brucella abortus
S19 among workers involved in vac-
cine production in Argentina. Clin.
Microbiol. Infect. 14, 805–807.
Wang, Y., Chen, Z., Qiao, F., Ying, T.,
Yuan, J., Zhong, Z., et al. (2009).
Comparative proteomics analyses
reveal the virB of B.melitensis affects
expression of intracellular survival
Frontiers in Cellular and Infection Microbiology www.frontiersin.org May 2013 | Volume 3 | Article 17 | 14
Gomez et al. Brucella subunit vaccine review
related proteins. PLoS ONE 4:e5368.
doi: 10.1371/journal.pone.0005368
Watanabe, K., Tachibana, M., Tanaka,
S., Furuoka, H., Horiuchi, M.,
Suzuki, H., et al. (2008). Heat shock
cognate protein 70 contributes to
Brucella invasion into trophoblast
giant cells that cause infectious
abortion. BMC Microbiol. 8:212.
doi: 10.1186/1471-2180-8-212
Watarai, M., Makino, S., Fujii, Y.,
Okamoto, K., and Shirahata, T.
(2002). Modulation of Brucella-
induced macropinocytosis by
lipid rafts mediates intracellu-
lar replication. Cell Microbiol. 4,
341–355.
Wattam, A. R., Williams, K. P., Snyder,
E. E., Almeida, N. F. Jr., Shukla,
M., Dickerman, A. W., et al. (2009).
Analysis of ten Brucella genomes
reveals evidence for horizontal gene
transfer despite a preferred intra-
cellular lifestyle. J. Bacteriol. 191,
3569–3579.
Wehrly, T. D., Chong, A., Virtaneva,
K., Sturdevant, D. E., Child, R.,
Edwards, J. A., et al. (2009).
Intracellular biology and virulence
determinants of Francisella tularen-
sis revealed by transcriptional
profiling inside macrophages. Cell
Microbiol. 11, 1128–1150.
Williams, E. (1970). Brucellosis and the
British public. Lancet 1, 1220–1222.
Wu, Q., Pei, J., Turse, C., and Ficht,
T. A. (2006). Mariner mutagen-
esis of Brucella melitensis reveals
genes with previously uncharacter-
ized roles in virulence and survival.
BMC Microbiol. 6:102. doi: 10.1186/
1471-2180-6-102
Yang, Y., Wang, L., Yin, J., Wang,
X., Cheng, S., Lang, X., et al.
(2011a). Immunoproteomic analy-
sis of Brucella melitensis and identi-
fication of a new immunogenic can-
didate protein for the development
of brucellosis subunit vaccine. Mol.
Immunol. 49, 175–184.
Yang, Y., Yin, J., Guo, D., Lang, X., and
Wang, X. (2011b). Immunization
of mice with recombinant S-
adenosyl-L-homocysteine hydrolase
protein confers protection against
Brucella melitensis infection. FEMS
Immunol. Med. Microbiol. 61,
159–167.
Yingst, S., and Hoover, D. L. (2003).
T cell immunity to brucel-
losis. Crit. Rev. Microbiol. 29,
313–331.
Zhan, Y., and Cheers, C. (1995).
Endogenous interleukin-12 is
involved in resistance to Brucella
abortus infection. Infect. Immun. 63,
1387–1390.
Zhan, Y., Liu, Z., and Cheers, C.
(1996). Tumor necrosis factor alpha
and interleukin-12 contribute to
resistance to the intracellular bac-
terium Brucella abortus by differ-
ent mechanisms. Infect. Immun. 64,
2782–2786.
Zhao, Z., Yan, F., Ji, W., Luo, D.,
Liu, X., Xing, L., et al. (2011).
Identification of immunoreactive
proteins of Brucella melitensis by
immunoproteomics. Sci. China Life
Sci. 54, 880–887.
Zvi, A., Rotem, S., Bar-Haim, E.,
Cohen, O., and Shafferman, A.
(2011). Whole-genome immunoin-
formatic analysis of F. tularensis:
predicted CTL epitopes clustered
in hotspots are prone to elicit
a T-cell response. PLoS ONE
6:e20050. doi: 10.1371/journal.
pone.0020050
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 16 October 2012; accepted: 26
April 2013; published online: 16 May
2013.
Citation: Gomez G, Adams LG, Rice-
Ficht A and Ficht TA (2013) Host-
Brucella interactions and the Brucella
genome as tools for subunit antigen dis-
covery and immunization against bru-
cellosis. Front. Cell. Infect. Microbiol.
3:17. doi: 10.3389/fcimb.2013.00017
Copyright © 2013 Gomez, Adams, Rice-
Ficht and Ficht. This is an open-access
article distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and subject to any copyright notices
concerning any third-party graphics etc.
Frontiers in Cellular and Infection Microbiology www.frontiersin.org May 2013 | Volume 3 | Article 17 | 15
